Navigation Links
Trius Raises $30 Million in Series B Financing
Date:3/23/2008

Kleiner Perkins Makes First Investment in Antibacterial Therapeutics From

its Biodefense and Pandemic Fund

SAN DIEGO, March 24 /PRNewswire/ -- Trius Therapeutics, Inc. today announced the close of a $30 million Series B financing to advance the clinical development of its best-in-class oxazolidinone antibacterial drug TR-701, now completing Phase I testing. The financing was led by Kleiner, Perkins, Caufield and Byers (KPCB). New investor FinTech Global Capital participated in the round, along with all existing investors -- Sofinnova Ventures, Versant Ventures, Interwest Partners and Prism VentureWorks.

"The excellent results from our ongoing Phase I trial, including data confirming the potential for once-daily dosing, prompted us to raise this round of financing earlier than initially planned to accelerate the clinical development of TR-701," stated Jeffrey Stein, Ph.D., President and CEO of Trius Therapeutics. "We are encouraged that KPCB has recognized our potential and joined our strong investor group. The proceeds from this financing will enable Trius to advance TR-701 through Phase II and into Phase III development, and to continue to invest in our pre-clinical programs."

In connection with the Series B investment, KPCB partner Risa Stack, Ph.D. will join the Trius board. "Trius represents our first investment in an antibacterial therapeutics company out of our Biodefense and Pandemic Fund" said Dr. Stack. "It signifies not only our confidence in the Trius programs and management, but also our concern over the growing unmet need for effective new antibacterial therapies."

About Trius Therapeutics

Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of infections caused by resistant pathogens. The company's lead drug candidate, TR-701 is a novel, oral and IV, oxazolidinone antibiotic with potent activity against drug-resistant Gram-positive bacterial pathogens including those resistant to Zyvox(R). Trius has licensed worldwide rights outside of Korea to TR-701 from Dong-A Pharmaceuticals. Trius' pipeline includes two additional structure-based drug design programs directed against novel antibacterial targets. For more information, visit http://www.triusrx.com.

About KPCB

KPCB began investing in and helping build life sciences companies in 1977 when it was the founding investor in Genentech. Since then, the firm and its Partners have backed entrepreneurs in 100 life science companies working in every area of medicine, including cardiology, cancer, neurology, immune system diseases, ophthalmology, and molecular diagnostics. Since its founding in 1972, KPCB has backed entrepreneurs in over 475 ventures, including AOL, Align Technology, Amazon.com, Citrix, Compaq Computers, Electronic Arts, Genentech, Genomic Health, Google, IDEC Pharmaceuticals, Intuit, Juniper Networks, Netscape, Lotus, LSI Logic, Sun Microsystems, Symantec, Verisign and Xilinx. More than 150 of the firm's portfolio companies have gone public. Many other ventures have achieved success through mergers and acquisitions.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals, Inc. Raises $5 Million
2. Two Parents With Alzheimers Raises Childs Risk
3. Oregon study raises questions on synthetic progestins
4. Childrens Burn Foundations Benefit Raises More Than $875,000 for Burn Survivors and Prevention
5. Harley-Davidson Womens Day Ride Raises Funds for MDAs Summer Camp Program
6. Clinical depression raises risk of death for heart attack patients years after attack
7. Spanking Raises Chances of Risky, Deviant Sexual Behavior
8. Drug for anemic cancer patients raises risk of death
9. Lotus Pharmaceuticals Raises $5 Million in Private Placement
10. Guatemalas Fundacion Ayudame a Vivir Fundraising Campaign Raises More Than $2.6 Million
11. Blunt Praises Presidents Plan to Save Medicare
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... D.C. (PRWEB) , ... February 13, 2016 , ... ... with Faces and Voices of Recovery, the leading national organization representing the growing ... urging candidates for public office to include Family Recovery in policies addressing addiction. ...
(Date:2/13/2016)... , ... February 13, 2016 , ... The producers of ... of American businesses. , The increasingly modern world of instantaneous consumption proves very ... non-renewable energy sources such as oil and coal, which pollutes our air, water, and ...
(Date:2/13/2016)... ... , ... When an Au Pair comes all the way around the world to ... and they are often worried things won’t go well. More often than not, however, they ... Pair of the Year winner’s all commented how their Au Pairs have become a part ...
(Date:2/12/2016)... Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... Vinci-assisted hernia surgeries are beginning to account for a significant portion of hernia repairs ... Shirin Towfigh of the Beverly Hills Hernia Center notes that this trend has not ...
(Date:2/12/2016)... Seattle, WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens ... technologies for low-resource settings. The partnership will recruit top students from U.S. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... CRANBURY, N.J. , Feb. 12, 2016  Innophos Holdings, ... performance-critical and nutritional specialty ingredients, today announced that it will ... at 10:00 am ET to discuss its fourth quarter and ... --> The press release detailing fourth quarter and ... 2016 after market close. --> ...
(Date:2/12/2016)... , Feb. 12, 2016  SI-BONE, Inc., a medical device company ... ("iFuse"), a minimally invasive surgical (MIS) device indicated for fusion for ... Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering the states ... Maine , Massachusetts , ... New York , Rhode Island , ...
(Date:2/12/2016)... -- On Thursday, Feb. 11, 2016, surgeons at the ... Austin Medical Center successfully completed the first robotic surgery ... Surgical System with Trumpf Medical,s advanced operating table, the ... M.D., colorectal surgeon at the Texas Institute for Robotic ... technology, which seamlessly combines the da Vinci Xi Surgical ...
Breaking Medicine Technology: